Child Examinations | North Tonawanda, NY

After Hour Nurse Advice Lines
phone iconPhone: (716) 807-7337
phone iconFax: (716) 213-4400
Receive our Health e-Newsletter


News for Healthier Living

Immune Activation May Determine Success of Dual-Target CAR T Therapy in Glioblastoma

Dual-target CAR T cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation linked to better patient outcomes and longer overall survival. CSF of individuals who did not respond to the therapy exhibited a higher proportion of activated regulatory T cells (Tregs) and high baseline levels of immunosuppressive scavenger myeloid cells, according to new research from the Perelman School of Medicine and Abramson Cancer Center at the University of Pennsylvania, published today in Cell.

June 15, 2026


June 26 2026

June 25 2026

June 24 2026

June 23 2026

June 22 2026

June 21 2026

June 19 2026

June 18 2026

June 17 2026

June 16 2026

June 15 2026

June 14 2026

June 13 2026